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et al. [8] reported that inﬂammation is associated with
hypoalbuminaemia and increased mortality in HD patients.
These studies and many others suggest that inﬂammation
plays a central role in the development of malnutrition and
cardiovascular mortality in patients with chronic kidney
disease. On the other hand, more recently, Pupim et al. [7]
showed that surrogate markers of nutritional status (S-
albumin, pre-albumin and serum creatinine) were, indeed,
signiﬁcantly related to all-cause mortality in HD patients,
even after adjustment for serum CRP. Although in our study
we could not conﬁrm a negative correlation between
S-albumin and CRP, taking into account only the baseline
measurements, it should be noted that in patients who were
persistently inﬂamed in our study, a negative correlation was,
indeed, found between S-albumin and CRP in the four
consecutive measurements preceding the study, demonstrat-
ing the inﬂuence of inﬂammation on S-albumin levels. We
could speculate why this ﬁnding could not be veriﬁed in the
patients who were not persistently inﬂamed. One reason
could be the high prevalence of malnutrition, veriﬁed by
SGA, in the Brazilian HD population, which differs from
American and European HD populations where the majority
of earlier studies on these relationships were done. Another
reason is that we excluded patients with clinically signiﬁcant
inﬂammatory events, which in turn could be reﬂected by the
absence of correlation in the whole studied HD population.
In summary, we agree with Tsirpanlis and colleagues that
(i) clinically signiﬁcant inﬂammatory events modify the levels
of S-albumin, (ii) this effect is not immediate and (iii) these
factors should be taken into account when analysing the
relationship between S-albumin and short acute-phase
reactants, such as CRP. We therefore advocate [9] sequential
measurements of CRP, which may provide a better approach
in the interpretation of decreasing S-albumin levels. On the
other hand, it seems reasonable to assume that the S-albumin
will remain as a valuable predictor of uraemic malnutrition,
inﬂammation and increased risk for mortality.
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Drug interaction between sevelamer and cyclosporin
This letter was originally published in NDT volume 19,
issue 7, but without the Reply. The publisher would like
to apologise for this error and would now like to publish the
paper again to include the Reply.
Sir,
We read with interest the original report made by
Miguel-Angel Guillen-Anaya and Michel Jadoul [1] of
a drug interaction between sevelamer and cyclosporin
(CsA) occurring in a liver transplant patient treated also
by chronic haemodialysis. After sevelamer was started,
the CsA trough levels reached values as low as 35 ng/ml
and they dropped again after rechallenge. As potential
explanation, the authors suggest that CsA absorption,
which is bile-dependent [2], could be hampered by the
fact that sevelamer binds bile acids in the gastrointestinal
(GI) tract. Interestingly, in the clinical study performed
by Jensen et al. [3], the bile-acid sequestrant cholestyr-
amine, 4 g given at noon, did not interfere with CsA
absorption.
We would like to mention that sevelamer is a poly(allyl-
aminehydrochloride) polymer that may bind not only
phosphate and bile acids, as the authors point out, but
also cholesterol, vitamins D, E and K and folic acid [4].
A direct binding of a lipophilic substance such as CsA – and
by extension also tacrolimus – appears, therefore, as an
additional and more likely explanation.
This observation points to the distinction to be made
between the two types of phosphate binding in the GI tract:
a speciﬁc one achieved by aluminium hydroxide and calcium
salts and a non-speciﬁc binding attained by polymers
such as sevelamer. This absence of speciﬁcity might be
of less importance for vitamins or folic acid absorption,
but may put the patient at risk when lipophilic agents, such
as immunosuppressive and/or other drugs (lipophilic
statins?), are prescribed. Under those circumstances, it
appears that sevelamer should be used with caution,
i.e. at least at a time distant of potentially interfering
drugs and only when speciﬁc (and less expensive) phosphate
binders are contraindicated.
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Reply
Sir,
We thank Jean-Pierre Wauters and colleagues for their
helpful comments. The lower level of cyclosporin A (CsA)
under sevelamer may indeed be due to a direct binding of
CsA by sevelamer, rather than to an indirect impact of
sevelamer on bile acids. Thus, the recommendation of a delay
between the intake of sevelamer and that of drugs such as
CsA is fully warranted. We disagree, however, on the claim
that calcium-based binding is fully speciﬁc for phosphate.
Indeed, the co-administration of either calcium acetate or
sevelamer with ciproﬂoxacin recently has been shown to
reduce the oral bioavailability of the latter drug by some 50%
[1].
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Sevelamer and pharmacokinetics of cyclosporin A
after kidney transplantation
Sir,
In their interesting article, Pieper et al. analysed prospectively
the effect of sevelamer on the pharmacokinetics of cyclo-
sporin (CsA) and mycophenolate mofetil (MMF) in kidney
transplanted patients [1]. They provide the reassuring
message that, in contrast to MMF, CsA kinetics are not
signiﬁcantly modiﬁed by the intake of sevelamer. These
results are in sharp contrast to the observation and potential
mechanisms that we reported recently [2,3].
The short duration (4 days) and limited statistical power
(10 adults and eight children) of the study of Pieper et al.
make such a strong message rather questionable [4]. Indeed,
only 4 days after starting sevelamer, none of the CsA
parameters (measured by Cedia and FPIA assays) was
completely stable: the area under the curve (AUC) decreased
from 3547±660 to 3230±612 ng/h/ml, Cmax decreased from
955±193 to 855±272 ng/ml and Tmax increased from 1.3
to 1.5 h. In addition, when measured with polyclonal anti-
bodies, the CsA levels decreased signiﬁcantly and, among
its primary metabolites determined by HPLC, the AUC and
Cmax of AM1—which also has an immunosuppressive action
[5]—decreased signiﬁcantly by 30 and 25%, respectively.
Despite these observations, the authors conclude that
‘sevelamer intake for several days does not signiﬁcantly
inﬂuence CsA kinetics’. Based on their data, this conclusion
appears at least premature, especially if the risk of transplant
rejection due to insufﬁcient immunosuppression is considered
[6]. Great caution in the use of sevelamer in transplanted
patients is still warranted until a careful long-term, large
size study on the potential interaction of sevelamer with CsA
solves the question.
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